Chest
-
Pleural Case Report PostersSESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Prolonged air leak (PAL) is the most common complication after pulmonary resection. In our settings PAL is defined as a postoperative persistent air leak of at least 5 days. We described 2 cases of PAL treated using endobronchial valves (EBV) placement. We have performed a retrospective review of 13 patients presenting with PAL after any type of pulmonary resection between January 2012 and August 2013. Data were obtained from our prospectively recorded database. Two of these patients were treated using EBV (Table 1). We describe patients' characteristics, clinical course, type of valves, complications and final outcome. ⋯ The following authors have nothing to disclose: Maria Rodríguez, María Teresa Gómez Hernández, Aldo Torracchi, Nuria María Novoa Valentín, Rosa Cordovilla, Jose Luis Aranda Alcaide, Marcelo Fernando Jiménez López, Gonzalo Varela SimóNo Product/Research Disclosure Information.
-
Tobacco Cessation and Prevention PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: To determine the prevalence of smoking in women diagnosed of Sleep Apnea-Hypopnea Syndrome (SAHS) in a service of respiratory medicine corresponding to a University Hospital, and its relationship with the severity of illness. ⋯ The following authors have nothing to disclose: Francisca Marquez, Maria Jose Antona, María Teresa Gómez Vizcaíno, Pilar Cordero Montero, Hernando Chávez RoldánNo Product/Research Disclosure Information.
-
COPD QVA149 PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Patients with severe COPD experience marked deterioration in lung function and breathlessness compared to patients with mild-to-moderate COPD. We report improvement of dyspnea and lung function in patients with severe COPD in the BLAZE study with QVA149, a dual bronchodilator combining the long-acting β2-agonist (LABA) indacaterol and the long-acting muscarinic antagonist (LAMA) glycopyrronium (NVA237), versus placebo and tiotropium. ⋯ Anthony D'Urzo: Consultant fee, speaker bureau, advisory committee, etc.: Novartis, AstraZeneca, Forest Laboratories, Pfizer, Schering Plough, Grant monies (from industry related sources): GSK, Schering Plough, Methapharma, AstraZeneca, Merck Canada, Forest Laboratories, Novartis Donald Mahler: Grant monies (from industry related sources): Boehringer Ingelheim, Novartis, and Sunovion, Consultant fee, speaker bureau, advisory committee, etc.: GlaxoSmithKline, Novartis, and Sunovion, and have served on Advisory Boards for Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pearl, and Sunovion Tracy White: Employee: Novartis Pharmaceuticals Corporation Vijay Alagappan: Employee: Novartis Pharmaceuticals Corporation Hungta Chen: Employee: Novartis Pharmaceuticals Corporation Karoly Kulich: Employee: Novartis Pharma AG Nicola Gallagher: Employee: Novartis Horsham Research Centre Donald Banerji: Employee: Novartis Pharmaceuticals Corporation The following authors have nothing to disclose: Heinrich WorthClinical trial results of QVA149, combination of two approved products indacaterol and glycopyrronium, will be presented, QVA149 is in the late stage phase 3 trials prior to approval.
-
Surgery CasesSESSION TYPE: Case ReportsPRESENTED ON: Sunday, March 23, 2014 at 09:00 AM - 10:00 AMINTRODUCTION: Cystic Fibrosis (CF) is a disease which can develop lung destruction and cause respiratory insufficiency in children. Lobar lung transplantation from adult donors has arisen as a treatment in some cases of respiratory failure in pediatric patients. ⋯ The following authors have nothing to disclose: Juan Pablo Reig, Amparo Sole, Emilio Ansótegui, Juan Escrivá, Juan Antonio PastorNo Product/Research Disclosure Information.
-
Symptoms of Respiratory Disease PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Studies of military personnel deployed to Operations Iraqi Freedom and Enduring Freedom have suggested an increase in chronic lung disease due to environmental exposures. Findings are based primarily on increased respiratory symptoms and retrospective data. Our previous study (STAMPEDE I) did not identify any acute interstitial or inflammatory process. The study objective was to complete a comprehensive evaluation of active duty military with deployment-related pulmonary symptoms and identify etiology of symptoms. ⋯ Michael Morris: Consultant fee, speaker bureau, advisory committee, etc.: Speaker Bureau for Spiriva with Pfizer/Boehringer/Ingelheim The following authors have nothing to disclose: Andrew Skabelund, Georgette Haislip, Pedro LuceroNo Product/Research Disclosure Information.